Over five days, from 23 to 27 October, researchers, clinicians and pharmaceutical companies are gathering in Madrid for the European Society for Medical Oncology’s (ESMO) annual congress, one of the world’s most important events for new cancer treatments.
AstraZeneca has several study results on the agenda. Among the most closely watched are new data for the company’s experimental antibody-drug conjugate (ADC) sonesitatug vedotin, known as sone-ve.
BREAKING